BRCA1/2 Mutations and Bevacizumab in the Neoadjuvant Treatment of Breast Cancer: Response and Prognosis Results in Patients With Triple-Negative Breast Cancer From the Gepar-Quinto Study - Fasching, P A; Loibl, S; Hu, C (J Clin Oncol, 2018)
et al.